# Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

> **NCT05308212** · PHASE2,PHASE3 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 633 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flu-M Tetra [Inactivated split influenza vaccine] w/p
- **BIOLOGICAL:** Flu-M Tetra [Inactivated split influenza vaccine] w/o/p
- **BIOLOGICAL:** Ultrix [Inactivated split influenza vaccine]

## Key facts

- **NCT ID:** NCT05308212
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-04
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-09-06
- **Target enrollment:** 633 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308212, "Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05308212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*